The prevalence of nonalcoholic fatty liver disease (NAFLD) has increased rapidly and is associated with obesity in epidemiology and pathogenesis. A new study reports that hepatic and extrahepatic complications can develop in lean individuals with NAFLD, highlighting the importance of metabolic phenotypes in NAFLD assessment instead of BMI-based approaches.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Ye, Q. et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 5, 739–752 (2020).
Younossi, Z. et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 15, 11–20 (2018).
Young, S. et al. Prevalence and Profile of Nonalcoholic Fatty Liver Disease in Lean Adults: Systematic Review and Meta-Analysis. Hepatol. Commun. 4, 953–972 (2020).
Sookoian, S. & Pirola, C. J. Systematic review with meta-analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease. Aliment. Pharmacol. Ther. 47, 16–25 (2018).
Younes, R. et al. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach? Gut https://doi.org/10.1136/gutjnl-2020-322564 (2021).
Chen, F. et al. Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation. Hepatology 71, 1213–1227 (2020).
Musso, G. et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 37, 909–916 (2003).
Albhaisi, S., Chowdhury, A. & Sanyal, A. J. Non-alcoholic fatty liver disease in lean individuals. JHEP Rep. 1, 329–341 (2019).
Koo, B. K. et al. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. J. Hepatol. 66, 123–131 (2017).
Eslam, M. et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J. Hepatol. 73, 202–209 (2020).
The authors declare no competing interests.
About this article
Cite this article
Ren, TY., Fan, JG. What are the clinical settings and outcomes of lean NAFLD?. Nat Rev Gastroenterol Hepatol 18, 289–290 (2021). https://doi.org/10.1038/s41575-021-00433-5
Metabolic Disorders Combined with Noninvasive Tests to Screen Advanced Fibrosis in Nonalcoholic Fatty Liver Disease
Journal of Clinical and Translational Hepatology (2021)